These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32639983)

  • 21. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study.
    Hamilton AS; Stanford JL; Gilliland FD; Albertsen PC; Stephenson RA; Hoffman RM; Eley JW; Harlan LC; Potosky AL
    J Clin Oncol; 2001 May; 19(9):2517-26. PubMed ID: 11331331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.
    Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB; Rossi PJ
    Brachytherapy; 2019; 18(1):13-21. PubMed ID: 30262410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality-of-life outcomes in men treated for localized prostate cancer.
    Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Leach GE; Brook RH
    JAMA; 1995 Jan; 273(2):129-35. PubMed ID: 7799493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.
    Sini C; Noris Chiorda B; Gabriele P; Sanguineti G; Morlino S; Badenchini F; Cante D; Carillo V; Gaetano M; Giandini T; Landoni V; Maggio A; Perna L; Petrucci E; Sacco V; Valdagni R; Rancati T; Fiorino C; Cozzarini C
    Radiother Oncol; 2017 Aug; 124(2):296-301. PubMed ID: 28739383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
    Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
    Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
    Lukka HR; Pugh SL; Bruner DW; Bahary JP; Lawton CAF; Efstathiou JA; Kudchadker RJ; Ponsky LE; Seaward SA; Dayes IS; Gopaul DD; Michalski JM; Delouya G; Kaplan ID; Horwitz EM; Roach M; Pinover WH; Beyer DC; Amanie JO; Sandler HM; Kachnic LA
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):287-295. PubMed ID: 29913254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rectal function following prostate brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of expanded prostate cancer index composite (EPIC) quality of life after surgery or radiation treatment.
    Lee TK; Breau RH; Mallick R; Eapen L
    Can J Urol; 2015 Feb; 22(1):7599-606. PubMed ID: 25694006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
    Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
    Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer.
    Henriksson R; Franzén L; Littbrand B
    J Clin Oncol; 1992 Jun; 10(6):969-75. PubMed ID: 1588377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodialysis patients' preferences for the management of secondary hyperparathyroidism.
    Hauber B; Caloyeras J; Posner J; Brommage D; Belozeroff V; Cooper K
    BMC Nephrol; 2017 Jul; 18(1):254. PubMed ID: 28750605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer.
    Ishii K; Yamanaga T; Ogino R; Hosokawa Y; Kishimoto S; Nakahara R; Shimada C; Kawamorita R; Tada T; Hayashi Y; Nakajima T
    Pract Radiat Oncol; 2018; 8(2):e49-e55. PubMed ID: 29310978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
    Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
    Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.